A Biomarker-Guided Therapeutic Map For Alopecia: In Vivo Evidence And Clinical Implications
June 2026
in “
PubMed
”
alopecia biomarker-guided therapeutic map TNF-α IL-6 MDA caspase-3 VEGF β-catenin inflammation immune damage oxidative stress apoptosis angiogenesis regeneration botanical extracts bioactive compounds advanced delivery systems tumor necrosis factor alpha interleukin-6 malondialdehyde vascular endothelial growth factor beta-catenin
TLDR A biomarker-guided approach can improve alopecia treatment by targeting specific pathways.
Alopecia involves complex disruptions in immune, oxidative, apoptotic, and regenerative pathways within the hair follicle microenvironment. This review highlights the potential of a biomarker-guided therapeutic map to improve treatment precision by focusing on six key biomarkers: TNF-α, IL-6, MDA, caspase-3, VEGF, and β-catenin. Analysis of 15 animal studies from 2014 to 2024 revealed that TNF-α and IL-6 are linked to inflammation and immune damage, MDA to oxidative stress, and caspase-3 to apoptosis. Conversely, VEGF and β-catenin, which support angiogenesis and regeneration, are suppressed in alopecia but can be restored through effective treatments. Therapeutic strategies such as botanical extracts, bioactive compounds, and advanced delivery systems have shown promise in reducing harmful biomarkers and enhancing regenerative pathways. This biomarker-centered approach offers a promising framework for developing targeted, multitargeted alopecia treatments.
